OVID Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ovid Therapeutics Inc (OVID) is not a strong buy for a beginner investor with a long-term focus at this time. The stock lacks positive momentum, has no recent significant news or catalysts, and hedge funds are selling. While analysts have raised price targets and maintain a Buy rating, the technical indicators and trading sentiment suggest caution. The absence of Intellectia Proprietary Trading Signals further supports a hold decision.
The MACD is negatively expanding, RSI is neutral at 40.585, and moving averages are converging. The stock is trading below the pivot level of 2.33, with key support at 2.201 and resistance at 2.459. Overall, the technical indicators do not suggest a strong buy opportunity.
Analysts have raised price targets and maintain a Buy rating, citing confidence in the company's pipeline, including OV4071 and OV329.
Hedge funds are selling heavily, with a 668.25% increase in selling over the last quarter. The stock has a 30% chance to decline in the short term based on candlestick pattern analysis. No recent news or congress trading data is available, and financial performance data is missing.
No financial data is available for assessment.
Analysts have raised price targets recently, with Roth Capital increasing the target to $7 and H.C. Wainwright increasing it to $4, both maintaining Buy ratings. However, these updates are based on long-term pipeline potential rather than immediate performance.
